TOKYO, April 1, 2021  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) annouced that Astellas and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, “Viatris”) have agreed to end the co-promotion of a hypercholesterolemia and familial hypercholesterolemia treatment (HMG-CoA reductase inhibitor) “Lipitor® Tablets 5mg, 10mg” (generic name: atorvastatin calcium hydrate, “Lipitor”) manufactured and sold by Astellas and co-promoted by both companies in Japan on July 31, 2021.

In accordance with this agreement, Viatris will solely promote and distribute Lipitor from August 1, 2021. Also, Viatris will take over the Marketing Authorization Holder of Lipitor from Astellas as of August 1, 2021. 

The impact ot this transaction on Astellas’ financial results of the current fiscal year ending March 31, 2021, is expected to be minor.

 

Click below for a copy of the full press release